The invention discloses dysentery polyvalence gene engineering vaccine. Its active constituent can express not only affecting albumen antigen IpaA, IpaB, IpaC, IpaD, but also fushi and songneishi double-valence LPS-O polysaccharide antigen. Its advantages are that it has good polyvalence immunogenicity to protect immunized mouse and monkey, resist S.F2a and S.sonnei; it can reduce immunizing dose, offer polyvalence protection to effectively defend bacillary dysentery; and it can be produced in large scale. |